ATE460473T1 - Immortalisierte entezelllinien zur viruserzeugung - Google Patents

Immortalisierte entezelllinien zur viruserzeugung

Info

Publication number
ATE460473T1
ATE460473T1 AT08101999T AT08101999T ATE460473T1 AT E460473 T1 ATE460473 T1 AT E460473T1 AT 08101999 T AT08101999 T AT 08101999T AT 08101999 T AT08101999 T AT 08101999T AT E460473 T1 ATE460473 T1 AT E460473T1
Authority
AT
Austria
Prior art keywords
cell lines
immortalized
virus generation
ent cell
ent
Prior art date
Application number
AT08101999T
Other languages
English (en)
Inventor
Volker Sandig
Ingo Jordan
Original Assignee
Probiogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34400514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE460473(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Probiogen Ag filed Critical Probiogen Ag
Application granted granted Critical
Publication of ATE460473T1 publication Critical patent/ATE460473T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10251—Methods of production or purification of viral material
    • C12N2710/10252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Manufacturing & Machinery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT08101999T 2003-11-03 2004-11-03 Immortalisierte entezelllinien zur viruserzeugung ATE460473T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03025158A EP1528101A1 (de) 2003-11-03 2003-11-03 Immortalisierte Vogel-Zelllinien für die Produktion von Viren

Publications (1)

Publication Number Publication Date
ATE460473T1 true ATE460473T1 (de) 2010-03-15

Family

ID=34400514

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08101999T ATE460473T1 (de) 2003-11-03 2004-11-03 Immortalisierte entezelllinien zur viruserzeugung
AT04798154T ATE398672T1 (de) 2003-11-03 2004-11-03 Immortalisierte vogelzellinien zur virusproduktion

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04798154T ATE398672T1 (de) 2003-11-03 2004-11-03 Immortalisierte vogelzellinien zur virusproduktion

Country Status (18)

Country Link
US (2) US8940534B2 (de)
EP (4) EP1528101A1 (de)
JP (1) JP4658953B2 (de)
KR (1) KR101027755B1 (de)
CN (1) CN1934243B (de)
AT (2) ATE460473T1 (de)
AU (1) AU2004285089B2 (de)
BR (1) BRPI0415622B8 (de)
CA (1) CA2544462C (de)
CY (1) CY1110272T1 (de)
DE (2) DE602004014526D1 (de)
DK (2) DK1939281T4 (de)
ES (1) ES2309578T3 (de)
PL (1) PL1685243T3 (de)
PT (1) PT1685243E (de)
RU (1) RU2359999C2 (de)
SI (1) SI1685243T1 (de)
WO (1) WO2005042728A2 (de)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1646715T3 (da) * 2003-07-22 2010-08-16 Vivalis Fremstilling af poxvirum med adhærente eller ikke-adhærente fuglecellelinjer
ATE489965T1 (de) 2004-09-09 2010-12-15 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
ES2525518T3 (es) 2005-11-01 2014-12-26 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual
CN102755645A (zh) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
JP2009514844A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
EP1783210A1 (de) * 2005-11-08 2007-05-09 ProBioGen AG Proteinfaktoren zur Erhöhung der Produktivität, neue Zelllinien und deren Verwendungen
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP4585610A3 (de) 2006-09-11 2025-09-24 Seqirus UK Limited Herstellung von influenzavirus-impfstoffen ohne verwendung von eiern
PT2121011E (pt) 2006-12-06 2014-07-31 Novartis Ag Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
EP1985305A1 (de) * 2007-04-24 2008-10-29 Vivalis Aus Entenembryonen gewonnene Stammzellkulturen zur Herstellung von Impfstoffen gegen Viren
KR20100045437A (ko) 2007-06-27 2010-05-03 노파르티스 아게 첨가물이 적은 인플루엔자 백신
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
JP5421250B2 (ja) 2007-07-03 2014-02-19 トランスジーン ソシエテ アノニム トリ不死化細胞株
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
AU2008339631B2 (en) 2007-12-24 2014-07-24 Novartis Ag Assays for adsorbed influenza vaccines
JP5653223B2 (ja) * 2008-02-25 2015-01-14 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 連続細胞系の生成方法
EP2098590A1 (de) 2008-03-04 2009-09-09 ProBioGen AG Zelllinie des Rosettenflughundes als Hostzelle für pathogene Verstärkung
US8679839B2 (en) * 2008-03-04 2014-03-25 Probiogen Ag Cell line from rousettus as host cell for pathogen amplification
JP5518041B2 (ja) 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
US20110229969A1 (en) * 2008-06-25 2011-09-22 Volker Sandig Cell Line for Propagation of Highly Attenuated AlphaViruses
EP2199385A1 (de) 2008-12-16 2010-06-23 ProBioGen AG Spezifische und persistente Aktivierung der Hitzeschockreaktion in Zelllinien mittels eines viralen Faktors
WO2010079081A1 (en) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
US20110293660A1 (en) 2009-02-06 2011-12-01 Bruno Rene Andre Novel method
EA201171032A1 (ru) 2009-02-10 2012-02-28 Новартис Аг Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
CA2752041A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
EP3173097A3 (de) 2009-02-10 2017-07-12 Seqirus UK Limited Influenzaimpfstoffe mit reduzierten anteilen an squalen
USH2283H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
CA2768186A1 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
JP5688373B2 (ja) * 2009-09-30 2015-03-25 国立大学法人帯広畜産大学 α−ガラクトースエピトープを発現するトランスジェニック鳥類、ウイルス及びワクチン
EP2531592A1 (de) 2010-02-04 2012-12-12 Vivalis Fed-batch-verfahren mit konzentriertem zellkulturmedium zur effizienten produktion von biologischen wirkstoffen bei eb66-zellen
US9494571B2 (en) 2010-03-08 2016-11-15 Novartis Ag Methods of testing for intracellular pathogens
US9744228B2 (en) 2010-04-07 2017-08-29 Norvartis Ag Method for generating a parvovirus B19 virus-like particle
US20130203151A1 (en) 2010-04-26 2013-08-08 Scott Balsitis Production of alphavirus replicon particles in packaging cells
CA2797059A1 (en) 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Novel method
US9426989B2 (en) 2010-05-06 2016-08-30 Novartis Ag Organic peroxide compounds for microorganism inactivation
CN103025350A (zh) 2010-05-21 2013-04-03 诺华有限公司 流感病毒的重配方法
CA2801151A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
WO2011151723A2 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens without lyophilization
AU2011276328C1 (en) 2010-07-06 2016-01-21 Novartis Ag Norovirus derived immunogenic compositions and methods
WO2012023044A1 (en) 2010-08-20 2012-02-23 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
WO2012051211A2 (en) 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms
AU2011325439B2 (en) 2010-11-02 2015-07-23 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Methods and vectors for cell immortalisation
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
WO2012103361A1 (en) 2011-01-26 2012-08-02 Novartis Ag Rsv immunization regimen
CA2835644C (en) 2011-05-13 2021-06-15 Novartis Ag Pre-fusion rsv f antigens
EP2724157B1 (de) 2011-06-27 2017-03-08 Valneva Screening-verfahren für zellen
EP2729165B1 (de) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogene kombinationszusammensetzungen und ihre verwendung
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
RU2014118727A (ru) 2011-10-11 2015-11-20 Новартис Аг Рекомбинантные самореплицирующиеся полицистронные молекулы рнк
US20140348863A1 (en) 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
EP2768528A1 (de) 2011-10-20 2014-08-27 Novartis AG Adjuvierte influenza-b-viren-impfstoffe für kinder
EP2660316A1 (de) 2012-05-02 2013-11-06 Helmholtz-Zentrum für Infektionsforschung GmbH Vogelzelllinie und deren Verwendung bei der Herstellung eines Proteins
US20150140068A1 (en) 2012-07-06 2015-05-21 Novartis Ag Immunogenic compositions and uses thereof
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
EP2922570A1 (de) 2012-11-20 2015-09-30 GlaxoSmithKline Biologicals SA Präfusionierte rsv-f-trimere
CN103060376A (zh) * 2012-12-11 2013-04-24 上海实验动物研究中心 一种禽腺病毒转移载体及其制备方法
CN109045294A (zh) 2013-01-10 2018-12-21 思齐乐 流感病毒免疫原性组合物及其应用
US20140255447A1 (en) * 2013-03-05 2014-09-11 Biomune Company Production of avian embryo cells
JP6851827B2 (ja) 2013-08-30 2021-03-31 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 細胞培養中でのウイルスの大規模製造
CN104726409B (zh) * 2013-12-19 2017-12-29 普莱柯生物工程股份有限公司 一种永生化的鸭胚肝细胞系的制备方法和应用
WO2015153708A1 (en) * 2014-04-02 2015-10-08 Synageva Biopharma Corp. Producing therapeutic proteins
EP2974739A1 (de) 2014-07-15 2016-01-20 Novartis AG RSVF-Trimerisierungsdomänen
RU2696312C2 (ru) 2014-07-16 2019-08-01 Трансген Са Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
US10428316B2 (en) 2014-12-04 2019-10-01 Intervet Inc. Immortalised chicken embryo fibroblasts
EP3031822A1 (de) 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus-Antigene
BE1023903B1 (fr) 2014-12-16 2017-09-08 Glaxosmithkline Biologicals Sa Nouveau procédé
US11147887B2 (en) 2014-12-17 2021-10-19 Fundación Para La Investigación Mèdica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of Wilson disease
US11118238B2 (en) 2014-12-17 2021-09-14 Fundación Para La Investigación Mèdica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of Wilson's disease and other conditions
EP3047856A1 (de) 2015-01-23 2016-07-27 Novartis AG Cmv-antigene und ihre verwendungen
EP4523756A3 (de) 2015-02-13 2025-05-28 Transgene Immunotherapeutischer impfstoff und antikörperkombinationstherapie
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
KR102790570B1 (ko) 2015-07-07 2025-04-04 세퀴러스 유케이 리미티드 인플루엔자 효능 검정
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
EP3481191A2 (de) * 2016-07-11 2019-05-15 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Systeme und verfahren zur züchtung von zellen in vitro
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
CN107012122A (zh) * 2016-12-12 2017-08-04 江苏省农业科学院 一种永生化鸡胚胎肝细胞系及其制备方法和用途
CN110168092A (zh) 2016-12-28 2019-08-23 特朗斯吉有限公司 溶瘤病毒和治疗分子
KR20260047644A (ko) 2017-03-30 2026-04-08 더 유니버서티 어브 퀸슬랜드 키메라 분자 및 그의 용도
WO2018234506A2 (en) 2017-06-21 2018-12-27 Transgene Sa PERSONALIZED VACCINE
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
EP3687561A4 (de) 2017-09-01 2021-06-09 The Australian National University Immunregulatorische moleküle und deren verwendung
EP3703723A4 (de) 2017-10-31 2021-12-15 KaliVir Immunotherapeutics, Inc. Onkolytischer plattformvektor zur systemischen abgabe
WO2019092002A1 (en) 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
EP3717505A4 (de) 2017-12-01 2021-12-01 Encoded Therapeutics, Inc. Gentechnisch veränderte dna-bindende proteine
WO2019219649A1 (en) 2018-05-14 2019-11-21 Vivet Therapeutics Gene therapy vectors comprising s/mar sequences
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
EP3820884B1 (de) 2018-07-13 2025-09-03 Valneva SE Verfahren zur wiederherstellung und erzeugung eines virus in vogelzellen
EP3617230A1 (de) 2018-09-03 2020-03-04 BioInvent International AB Neuartige antikörper und nukleotidsequenzen und verwendungen davon
CN110396496B (zh) * 2018-09-30 2023-06-20 湖北省农业科学院畜牧兽医研究所 一种鸭小肠上皮细胞的培养方法及应用
US20210292791A1 (en) 2018-10-12 2021-09-23 Vivet Therapeutics Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3)
CN109321516A (zh) * 2018-11-07 2019-02-12 贵州大学 一种鸭原代肝细胞分离及培养方法
AU2019375450A1 (en) 2018-11-07 2021-06-17 Vivet Therapeutics Codon-optimized ABCB11 transgene for the treatment of progressive familial intrahepatic cholestasis type 2 (PFIC2)
EP3880809A4 (de) 2018-11-16 2023-01-11 Encoded Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von morbus wilson
SG11202104869SA (en) 2018-11-23 2021-06-29 Valneva Se Food products comprising avian stem cells
US12478571B2 (en) 2018-12-17 2025-11-25 Pontis Biologics, Inc. Enzyme based compositions and methods for removing dental calculi
US20220056481A1 (en) 2018-12-28 2022-02-24 Transgene M2-defective poxvirus
EP3686276A1 (de) * 2019-01-28 2020-07-29 Freie Universität Berlin Produktion von viren in kontinuierlich wachsenden epithelialen zelllinien aus hühnerdarm
PL3976798T3 (pl) 2019-05-29 2026-04-07 Encoded Therapeutics, Inc. Kompozycje i sposoby selektywnej regulacji genów
JP7852185B2 (ja) 2019-07-02 2026-04-28 フンダシオン・パラ・ラ・インベスティガシオン・メディカ・アプリカダ ｃＰＬＡ２ｅ誘導剤及びその使用
US20220273789A1 (en) 2019-07-21 2022-09-01 Glaxosmithkline Biologicals Sa Therapeutic viral vaccine
WO2021014385A1 (en) 2019-07-24 2021-01-28 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
EP4061930A1 (de) 2019-11-18 2022-09-28 Seqirus Pty Ltd Verfahren zur herstellung von reassortierenden influenza-viren
JP2021136899A (ja) * 2020-03-04 2021-09-16 花王株式会社 ウイルス増殖方法及びウイルス増殖促進剤の探索方法
WO2021209897A1 (en) 2020-04-13 2021-10-21 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
CN116322740A (zh) 2020-07-13 2023-06-23 特兰斯吉恩股份有限公司 免疫抑制的治疗
CN116390773A (zh) 2020-08-06 2023-07-04 应用医学研究基金会 用于通过基因疗法治疗诸如阿尔茨海默病的Tau蛋白病的病毒颗粒
US20230265456A1 (en) 2020-08-10 2023-08-24 Fundacion Para La Investigacion Medica Aplicada Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
IL301255A (en) 2020-10-09 2023-05-01 UCB Biopharma SRL Nucleic acid structures, viral vectors and viral particles
TW202227621A (zh) 2020-11-19 2022-07-16 美商凱立凡爾免疫治療股份有限公司 重塑腫瘤微環境的溶瘤免疫療法
WO2022136616A1 (en) 2020-12-23 2022-06-30 Vivet Therapeutics Minimal bile acid inducible promoters for gene therapy
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
AU2022206415A1 (en) 2021-01-10 2023-08-17 Supermeat The Essence Of Meat Ltd. Pluripotent stem cell aggregates and microtissues obtained therefrom for the cultured meat industry
EP4032547A1 (de) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce abgeleitete fragemente zur hsv therapie
BR112023022681A2 (pt) 2021-04-30 2024-01-23 Kalivir Immunotherapeutics Inc Vírus oncolíticos para expressão modificada de mhc
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
TW202321458A (zh) 2021-09-22 2023-06-01 瑞典商生物創新國際公司 新穎抗體組合及其用途
EP4419650A1 (de) 2021-10-18 2024-08-28 Supermeat the Essence of Meat Ltd. Verfahren zur herstellung eines nahrungsmittelbestandteils und dadurch hergestellte zusammensetzungen
EP4423286A1 (de) 2021-10-28 2024-09-04 UCB Biopharma SRL Nukleinsäurekonstrukte, virale vektoren und virale partikel
CN114350601B (zh) * 2021-12-21 2022-12-27 广东省华晟生物技术有限公司 樱桃谷鸭成纤维细胞系及其构建方法与应用
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CN114908053A (zh) * 2022-04-24 2022-08-16 上海交通大学 孔雀成纤维永生化细胞系的制备方法及其在病毒扩增中的应用
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
AU2023300419A1 (en) 2022-07-01 2025-01-02 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
US20260049291A1 (en) 2022-08-18 2026-02-19 Transgene Chimeric poxviruses
CN116496992B (zh) * 2023-04-24 2023-12-01 江苏省家禽科学研究所 一种鸡胚成肌永生化细胞及其构建方法和应用
WO2025120141A1 (en) * 2023-12-08 2025-06-12 Bavarian Nordic A/S Downregulation of yield-reducing transgenes expressed by poxvirus
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160406A0 (en) 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
KR970010968A (ko) 1995-08-24 1997-03-27 윤원영 오리 배 세포를 이용한 에리스로포이틴의 발현 시스템
US5989805A (en) 1995-10-27 1999-11-23 Board Of Trustees Operating Michigan State University Immortal avian cell line to grow avian and animal viruses to produce vaccines
FR2749022B1 (fr) * 1996-05-23 2001-06-01 Rhone Merieux Cellules aviaires immortelles
US5830723A (en) 1996-08-13 1998-11-03 Regents Of The University Of Minnesota Method for immortalizing chicken cells
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
FR2767335B1 (fr) 1997-08-14 2001-09-28 Ct Nat D Etudes Veterinaires E Adenovirus aviaire celo recombinant comme vecteur vaccinant
DE19955558C2 (de) * 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
CN1139655C (zh) * 2001-08-23 2004-02-25 北京大学人民医院 一种人卵巢癌永生化细胞株及其建立方法
WO2004015118A1 (en) 2002-08-07 2004-02-19 Bavarian Nordic A/S Vaccinia virus host range genes to increase the titer of avipoxviruses
ES2305514T5 (es) 2002-09-05 2019-06-14 Bavarian Nordic As Método para la amplificación de un poxvirus en condiciones exentas de suero
DK1646715T3 (da) 2003-07-22 2010-08-16 Vivalis Fremstilling af poxvirum med adhærente eller ikke-adhærente fuglecellelinjer

Also Published As

Publication number Publication date
DK1939281T4 (da) 2014-08-25
KR101027755B1 (ko) 2011-04-07
CY1110272T1 (el) 2015-01-14
US20080227146A1 (en) 2008-09-18
JP4658953B2 (ja) 2011-03-23
ATE398672T1 (de) 2008-07-15
DK1685243T3 (da) 2008-10-20
PL1685243T3 (pl) 2008-12-31
US20120288916A1 (en) 2012-11-15
SI1685243T1 (sl) 2008-12-31
AU2004285089B2 (en) 2009-07-02
BRPI0415622A (pt) 2006-12-12
DK1939281T3 (da) 2010-06-14
EP1685243A2 (de) 2006-08-02
EP2192173A1 (de) 2010-06-02
BRPI0415622B8 (pt) 2021-05-25
EP1939281A1 (de) 2008-07-02
EP1939281B1 (de) 2010-03-10
WO2005042728A3 (en) 2005-07-07
BRPI0415622B1 (pt) 2021-01-26
KR20060123758A (ko) 2006-12-04
PT1685243E (pt) 2008-09-24
US8940534B2 (en) 2015-01-27
CA2544462C (en) 2011-10-25
EP1685243B1 (de) 2008-06-18
ES2309578T3 (es) 2008-12-16
RU2359999C2 (ru) 2009-06-27
EP1939281B2 (de) 2014-06-04
AU2004285089A1 (en) 2005-05-12
CN1934243A (zh) 2007-03-21
EP1528101A1 (de) 2005-05-04
DE602004014526D1 (de) 2008-07-31
CN1934243B (zh) 2011-07-06
DE602004025996D1 (de) 2010-04-22
WO2005042728A2 (en) 2005-05-12
RU2006119447A (ru) 2007-12-20
CA2544462A1 (en) 2005-05-12
JP2007510409A (ja) 2007-04-26

Similar Documents

Publication Publication Date Title
ATE460473T1 (de) Immortalisierte entezelllinien zur viruserzeugung
ATE466932T1 (de) Vermehrung von viren in zellkultur
ATE547511T1 (de) Nichttumorbildende mdck-zellinie zur vermehrung von viren
WO2007048089A3 (en) Multi-plasmid system for the production of influenza virus
WO2019139645A3 (en) High efficiency base editors comprising gam
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
EA201200217A1 (ru) Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
BR112013007862A2 (pt) ácidos nucleicos manipulados e métodos de uso dos mesmos.
BRPI0809842A8 (pt) processo para a obtenção de linhagens de células aviárias diploides contínuas, processo de replicação de um vírus em uma linhagem de células aviárias diploides contínuas e processo de produção de peptídeos e proteínas recombinantes
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
EA201001045A1 (ru) Модифицированный вирус гриппа
ATE469972T1 (de) Multiplasmid-system zur erzeugung des grippevirus
CY1110525T1 (el) Βελτιστοποιημενη εκφραση της hpv 45 li σε ζυμη
CL2008003794A1 (es) Virus de la estomatitis vesicular geneticamente modificado (vsv) que comprende por lo menos una mutacion de aminoacido en una region de alguna de las proteinas m, g y l del virus; metodo para producirlo; composicion inmunogenica que lo comprende; metodo para adaptar un virus en un cultivo celular.
BRPI0612268A2 (pt) Ácido nucleico isolado, vetor de expressço, mÉtodos para produzir um rna genâmico da influenza, para produzir um vÍrus da influenza recombinante, para gerar um vÍrus de rna segmentado de filamento negativo recombinante nas cÉlulas caninas cultivadas e para gerar partÍculas virais da influenza infecciosa em cÉlulas caninas cultivadas, cÉlula, e, vÍrus
EA201390856A1 (ru) Инактивация вирусов с применением улучшенного способа растворитель-детергент
AU2007240448A8 (en) Methods and compositions for expressing negative-sense viral RNA in canine cells
BRPI0509497A (pt) seqüência de polipeptìdeos na modulação do efeito imunosupressor de proteìnas virais
ATE507242T1 (de) Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
BRPI0508928A (pt) fator de permissividade celular para vìrus e usos do mesmo
EP1989316A4 (de) Verfahren zur herstellung von rekombinantem virus, dna-konstrukte, rekombinantes virus und impfstoffzusammensetzungen
WO2005115448A8 (en) Multi plasmid system for the production of influenza virus
ATE408013T1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
AR024122A1 (es) Metodo para la estabilizacion intensificada de proteinas y produccion de lineas celulares que sirven para la produccion de dichas proteinas estabilizadas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1939281

Country of ref document: EP